Prevention of First Stroke: Current Recommendations
TABLE
National Stroke Association Summary Recommendations for Prevention of a First Stroke
Condition
Reccomendation
Hypertension The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommendations for lifestyle modification, initiation of specific therapy and multidisciplinary management strategies Myocardial infarction Aspirin therapy if previous MI or warfarin at an INR of 2 to 3 in patients with atrial fibrillation, left ventricular thrombus or significant left ventricular dysfunction, and statin agents after an MI in patients with normal to high lipid levels Atrial fibrillation Patients >75 years with or without risk factors should be treated with warfarin; patients 65 to 75 years with risk factors should be treated with warfarin and those without risk factors should be treated with warfarin or aspirin; patients <65 years with risk factors should be treated with warfarin; those without risk factors should be treated with aspirin Diabetes mellitus American Diabetes Association recommendations for controlof diabetes to reduce microvascular complications (further studies are needed to determine if aggressive glycemic control lowers the risk of stroke) Lipid levels Statin agents in patients with high cholesterol and coronary heart disease and National Cholesterol Education Program guideline principles for dietary and pharmacologic management of patients with hyperlipidemia or atherosclerotic disease Asymptomatic cartoid artery disease Carotid endarterectomy for asymptomatic carotid stenosis >=60% (but <100%) Lifestyle factor Modification of smoking, alcohol consumption, physical activity and diet according to published guidelines
MI = myocardial infarction; INR = International Normalized Ratio.
Adapted with permission from Laupacis A, Albers G, Dalen J, Dun MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 1998;114:579-89.Stroke remains a leading cause of morbidity and mortality in the United States, despite the fact that it is a preventable condition. Known risk factors include hypertension, myocardial infarction (MI), atrial fibrillation, diabetes mellitus, hyperlipidemia, carotid artery disease and lifestyle choices. Early recognition of these risk factors plays an important role in reducing the incidence of first stroke. Gorelick and colleagues, writing for the Advisory Board of the National Stroke Association (NSA), reviewed the literature from 1990 to mid-1998 to produce a consensus statement outlining their recommendations for prevention of first stroke. The MEDLINE database was searched for relevant guidelines, meta-analyses and statements. The listed risk factors were also reviewed.
Hypertension is the most common, yet the most preventable, risk factor for stroke, and its treatment reduces the risk of stroke significantly. Decreasing diastolic blood pressure by only 5 to 6 mm Hg reduces the risk of stroke by 42 percent. Treatment of isolated systolic hypertension in the elderly reduces the risk by 36 percent. The NSA recommends three strategies for lowering blood pressure: (1) controlling blood pressure in at-risk patients with hypertension; (2) encouraging at-home monitoring of blood pressure in patients with hypertension; and (3) checking blood pressure of all patients at every physician visit. Treatment with antihypertensive agents is useful in decreasing the morbidity associated with stroke. Diuretics offer a 39 percent odds reduction, and beta blockers a 25 percent odds reduction in older patients with hypertension.
The risk of stroke is only 1 to 2 percent a year following an MI but is much greater (31 percent) in the first month after an MI. The NSA recommends warfarin therapy in patients with an MI and either persistent atrial fibrillation, decreased left ventricular function or left ventricular thrombi within several months after the MI. Unless at least one of these risk factors is present with an MI, warfarin therapy should not be used, as the absolute risk reduction is only about 1 percent a year. Antiplatelet agents reduce the odds of nonfatal stroke by 39 percent in patients with a history of an MI, but the absolute stroke risk reduction is too small to be useful in preventing a first stroke after an MI. The NSA recommends statin therapy in patients with normal to high lipid levels following an MI, as these agents offer a 31 percent risk reduction for stroke, compared with a placebo.
Nonvalvular atrial fibrillation (NVAF) is another common risk factor for stroke. Warfarin reduces the incidence of stroke by 68 percent in patients with NVAF and risk factors for stroke. Aspirin reduces the risk by 21 percent. The NSA recommends that patients younger than 65 years of age with NVAF and no risk factors for stroke should take 325 mg of aspirin daily, while patients with risk factors should be given warfarin (with an INR goal of 2.0 to 3.0). Older patients, between 65 and 75 years of age, with NVAF and risk factors should receive warfarin, but those without risk factors can be given either warfarin or aspirin. All patients with NVAF who are older than 75 years should be given warfarin. The risk of stroke should be weighed against the risk of hemorrhage in all cases. For more information, see the accompanying table listing complete NSA recommendations for prevention of a first stroke.
GRACE BROOKE HUFFMAN, M.D.
Gorelick PB, et al. Prevention of a first stroke. A review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA March 24/31, 1999;281:1112-20.
Copyright © 1999 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.
